180 related articles for article (PubMed ID: 34161621)
1. Long-term efficacy and safety of ustekinumab for moderate-to-severe psoriasis: A 9-year real-life experience from a tertiary referral center in Turkey.
Babuna Kobaner G; Polat Ekinci A; Kutlay A
Dermatol Ther; 2021 Jul; 34(4):e15042. PubMed ID: 34161621
[TBL] [Abstract][Full Text] [Related]
2. A real life experience with ustekinumab: The effectiveness of 45 mg on patients greater than 80 kg but lower than 100 kg.
Koç Yıldırım S; Demirel Öğüt N; Erbağcı E; Hapa FA
Dermatol Ther; 2022 Jun; 35(6):e15494. PubMed ID: 35384189
[TBL] [Abstract][Full Text] [Related]
3. Ustekinumab treatment for moderate to severe psoriasis. Eight-year real-world follow-up of 61 cases in a tertiary level hospital.
Elberdín L; Fernández-Torres R; Paradela S; Blanco E; Outeda M; Martín I; Fonseca E
J Dermatolog Treat; 2020 Nov; 31(7):698-701. PubMed ID: 30961404
[No Abstract] [Full Text] [Related]
4. Ustekinumab in psoriasis: Five-year real life experience from a single tertiary centre.
Acer E; İğrek A; Erdoğan HK; Saracoğlu ZN
Dermatol Ther; 2020 Mar; 33(2):e13224. PubMed ID: 31917491
[TBL] [Abstract][Full Text] [Related]
5. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS).
Gargiulo L; Ibba L; Malagoli P; Angileri RG; Bardazzi F; Bernardini N; Burlando M; Carrera CG; Chiricozzi A; Dapavo P; Dini V; Fabbrocini G; Gaiani FM; Galluzzo M; Giofré C; Guarneri C; Loconsole F; Malara G; Marcelli L; Megna M; Piaserico S; Talamonti M; Costanzo A; Narcisi A
J Eur Acad Dermatol Venereol; 2023 May; 37(5):1017-1027. PubMed ID: 36695061
[TBL] [Abstract][Full Text] [Related]
6. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
Papp KA; Gordon KB; Langley RG; Lebwohl MG; Gottlieb AB; Rastogi S; Pillai R; Israel RJ
Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
[TBL] [Abstract][Full Text] [Related]
7. Clinical factors predicting the therapeutic response to ustekinumab in patients with moderate to severe chronic plaque psoriasis.
Hwang YJ; Youn SW; Kim BR; Yu DY; Kim Y; Pires A; Cho S; Seo SJ; Lee ES; Roh JY; Choi GS; Lee MG;
J Dermatol; 2017 May; 44(5):560-566. PubMed ID: 27864841
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes in adult patients with plaque psoriasis treated with ustekinumab under real-world practice in Korea: A prospective, observational, multi-center, postmarketing surveillance study.
Youn SW; Yu DY; Kim BS; Kim Y; Kim KJ; Choi JH; Son SW; Lee ES; Ro YS; Park YL; Lee Y; Lee JH; Park HJ; Kim TY; Lee MG; Shin MK; Choi GS; Kim DH; Jo SJ; Lee SC;
J Dermatol; 2021 Jun; 48(6):778-785. PubMed ID: 33528054
[TBL] [Abstract][Full Text] [Related]
9. Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience.
Galluzzo M; D'Adamio S; Silvaggio D; Lombardo P; Massaro A; Egan CG; Bianchi L; Talamonti M
Expert Opin Biol Ther; 2020 Jan; 20(1):95-104. PubMed ID: 31640431
[No Abstract] [Full Text] [Related]
10. Clinical evidence on the use of brodalumab for the treatment of psoriasis in Greece: Experience from clinical practice of four tertiary hospitals.
Tampouratzi E; Papakonstantis M; Katsantonis J; Sidiropoulos T; Delli F; Efthymiadis K; Sfaelos K; Christodoulou A; Chasapi V; Panagakis P
Dermatol Ther; 2022 Jul; 35(7):e15532. PubMed ID: 35451147
[TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of ustekinumab for treatment of moderate to severe psoriasis: a prospective study in a clinical setting.
Molina-Leyva A; Husein-Elahmed H; Naranjo-Sintes R; Ruiz-Carrascosa JC
J Drugs Dermatol; 2014 Aug; 13(8):971-4. PubMed ID: 25116977
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
Kimball AB; Gordon KB; Fakharzadeh S; Yeilding N; Szapary PO; Schenkel B; Guzzo C; Li S; Papp KA
Br J Dermatol; 2012 Apr; 166(4):861-72. PubMed ID: 22356258
[TBL] [Abstract][Full Text] [Related]
14. Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis.
Meng Y; Dongmei L; Yanbin P; Jinju F; Meile T; Binzhu L; Xiao H; Ping T; Jianmin L
Clin Exp Dermatol; 2014 Aug; 39(6):696-707. PubMed ID: 25039593
[TBL] [Abstract][Full Text] [Related]
15. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice.
Vilarrasa E; Notario J; Bordas X; López-Ferrer A; Gich IJ; Puig L
J Am Acad Dermatol; 2016 Jun; 74(6):1066-72. PubMed ID: 27004803
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of adalimumab versus ustekinumab in the treatment of severe chronic plaque psoriasis: The results based on data from the program "treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland.
Owczarek W; Nowakowska A; Walecka I; Ciechanowicz P; Reich A; Lesiak A; Borkowska E; Śliwczyński A; Narbutt J
Dermatol Ther; 2022 Jun; 35(6):e15481. PubMed ID: 35363386
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
[TBL] [Abstract][Full Text] [Related]
18. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.
Carrera CG; Dapavo P; Malagoli P; Naldi L; Arancio L; Gaiani F; Egan CG; Di Mercurio M; Cattaneo A
J Dermatolog Treat; 2018 Aug; 29(5):481-486. PubMed ID: 29058948
[TBL] [Abstract][Full Text] [Related]
19. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
[TBL] [Abstract][Full Text] [Related]
20. Ustekinumab in clinical practice: response depends on dose and previous treatment.
Ruiz Salas V; Puig L; Alomar A
J Eur Acad Dermatol Venereol; 2012 Apr; 26(4):508-13. PubMed ID: 22077903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
